qtc trials presented by: ad roffel, ph.d. pra international eds nl p.o. box 200, 9470 ae zuidlaren,...
TRANSCRIPT
![Page 1: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/1.jpg)
QTc Trials
Presented By:
Ad Roffel, Ph.D.PRA International EDS NLP.O. Box 200, 9470 AE Zuidlaren, The NetherlandsTel: +31 50 402 22 22Fax: +31 50 402 22 23
-Adopted guidance-Clinical execution-Outcome-Conclusions
![Page 2: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/2.jpg)
2The Project Assurance® Difference
QT/QTc-interval
![Page 3: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/3.jpg)
4The Project Assurance® Difference
Adopted Guidance - History
CPMP Points to Consider• December 1997
HC Draft Guidance• March 2001
FDA/HC Concept Paper• November 2002
Adopted as ICH Topic• July 2003 (Step 1)
ICH Final Draft Text• May 2005 (Step 4)
Current Practice• October 2005 (FDA)• November 2005 (CHMP)
![Page 4: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/4.jpg)
5The Project Assurance® Difference
Adopted Guidance - Contents
All new drugs require thorough QTc trial, irrespective of preclinical profileAlso required for approved products that apply for new registration (dose, indication, target population, route of administration)Needs to define a 5-ms effect with a one-sided 95% CI that excludes a 10-ms effect, using time-matched methods with 3-5 ECGs per time point Randomised, double-blind, placebo, positive control, therapeutic dose level, supratherapeutic dose level (multiples of the maximum expected concentration), healthy volunteers
New, complex, expensive study required for all registration dossiers
![Page 5: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/5.jpg)
6The Project Assurance® Difference
Adopted GuidanceClinical Execution• Planning• Design• Safety• Operational• Data analysis
OutcomeConclusions
![Page 6: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/6.jpg)
7The Project Assurance® Difference
Place in development programAs early as possibleAfter PK and metabolism have been sufficiently characterized
•Cmax of parent and active metabolites•Dose regimen in therapeutic use•Supratherapeutic dose
Outcome may direct intensity of ECG monitoring in Phase III
Early to late Phase II
Clinical Execution - Planning
![Page 7: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/7.jpg)
8The Project Assurance® Difference
Timing, timelinesTime from RFP to First-Subject-In: 3 - 4 months• thorough discussion on design (Sponsor, CRO, FDA)• big studies: proper preparation, timely recruitment
First-Subject-In to Last-Subject-Out: 4 weeks - 3 months• single dose, 4-way cross-over (n=44 subjects)• parallel, multiple dose titration (n=80 subjects)
Clinical Execution - Planning
![Page 8: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/8.jpg)
9The Project Assurance® Difference
Adopted GuidanceClinical Execution• Planning• Design• Safety• Operational• Data analysis
OutcomeConclusions
![Page 9: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/9.jpg)
10The Project Assurance® Difference
Design – Supratherapeutic dose
(E14) Worst case exposure should be mimicked (“substantial multiples of anticipated maximum therapeutic exposure”)• genetic variation, concomitant disease or medication
Use of metabolic inhibitors to reach supratherapeutic plasma concentrations may be considered
Experience(FDA) Supratherapeutic dose 2- to 20-fold therapeutic dose (median: 4-fold)(PBR) 2- to 10-fold (5-fold); Maximum Tolerated Dose, or maximum dose ever given
![Page 10: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/10.jpg)
11The Project Assurance® Difference
Design - Positive control
Assay sensitivity vs. reference for outcomeMoxifloxacin• Widely used• Consistent QTc-prolongation of 6-15 ms at 400 mg p.o.• No risk of TdP• Single dose is sufficient, also in multiple dose designs
Drug from same class could serve as reference, but usually less characterizedPositive control can be open, no need to blind
![Page 11: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/11.jpg)
12The Project Assurance® Difference
Design - Sample size
Postulated drug-induced effect (e.g., 0 ms, 3 ms, 6 ms)Intra- / inter-subject variability (SD) in QTc (6-12 ms)Upper bound 95% CI to be excluded (10 ms)Required power
![Page 12: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/12.jpg)
13The Project Assurance® Difference
Design - Variability in QTc
30%
40%
50%
60%
70%
80%
90%
100%
0 10 20 30 40 50 60 70
number of subjects (n)
Po
wer
(%)
![Page 13: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/13.jpg)
14The Project Assurance® Difference
Design - Sources of QTc variability
Correction for heart rate (RR): individual correction method (QTci)• Alternatives: Bazett, Fredericia (QTcB, QTcF) – required for historic
reasonsDiurnal variation • Usually 12-16 time-points over 24 h with at least 3 ECGs at each time
point• ECGs should cover Cmax of parent and metabolites
Population: male and female healthy volunteers, age 18-45 (65)Conditions of the ECG collection• Supine rest, mental activity, before blood sampling, meals
Proper design of baseline dayECG collection and QT measurement (validated core ECG laboratory)• Digital processing, manual evaluation
![Page 14: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/14.jpg)
15The Project Assurance® Difference
Design – Inclusion criteria
Age• Classically: 18-45 years (higher age increases
frequency of co‑morbidity)
• In specific cases: relate to target population Gender• Males and females required: at least 40% each
Race• Limited data: unclear whether ethnic factors play a role
in QTc prolongation Smoking habits• Classically: non- or light smokers allowed
![Page 15: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/15.jpg)
16The Project Assurance® Difference
Design - Options
Therapeutic doseSupra-therapeutic dosePositive controlPlacebo
Cross-over
Parallel
Alternative parallel
N=50
N=200
N=150
![Page 16: QTc Trials Presented By: Ad Roffel, Ph.D. PRA International EDS NL P.O. Box 200, 9470 AE Zuidlaren, The Netherlands Tel: +31 50 402 22 22 Fax: +31 50 402](https://reader035.vdocuments.site/reader035/viewer/2022062713/56649ce35503460f949af73d/html5/thumbnails/16.jpg)
17The Project Assurance® Difference
Click here to continue